Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9UHV7
UPID:
MED13_HUMAN
Alternative names:
Activator-recruited cofactor 250 kDa component; Mediator complex subunit 13; Thyroid hormone receptor-associated protein 1; Thyroid hormone receptor-associated protein complex 240 kDa component; Vitamin D3 receptor-interacting protein complex component DRIP250
Alternative UPACC:
Q9UHV7; B2RU05; O60334
Background:
Mediator of RNA polymerase II transcription subunit 13, also known as Mediator complex subunit 13, plays a pivotal role in the regulated transcription of nearly all RNA polymerase II-dependent genes. It acts as a bridge, conveying information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery, facilitating the assembly of a functional preinitiation complex.
Therapeutic significance:
The protein is implicated in Intellectual developmental disorder, autosomal dominant 61, characterized by developmental delays, behavioral abnormalities, and variable dysmorphic features. Understanding the role of Mediator of RNA polymerase II transcription subunit 13 could open doors to potential therapeutic strategies for this disorder.